Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions:
In cancer, ?? T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. ?? T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.
The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. ?? T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.
TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic ?? T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global ?? T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other ?? T cell candidates in development for various cancer indications.
One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of ?? T cells and substantiates their role as a new therapeutic strategy.
Globally, most of the research studies on ?? T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply ?? T cell treatments to these more difficult contexts. Geographically, US-based players dominate the ?? T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.
Moving forward, the prospects for ?? T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of ?? T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.
Companies Mentioned
Acepodia
Adicet
Appia Bio
Cytomed Therapeutics
Century Therapeutics
Expression Therapeutics
Immatics
IN8bio
JY BioMed
Legend Biotech
Luminary Therapeutics
PhosphoGam
Takeda
TC Biopharm
ViGenCell
Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions:
- Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies
- Highest Phase Of Development: Phase II/III
- As Of June’2025 No Gamma Delta T Cells Therapy Is Commercially Available
- US & China Dominating Gamma Delta T Cell Therapies Clinical Trials Landscape: > 20 Therapies
- Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
- Gamma Delta T Cell Therapies Technology Platforms Insight By Company : > 15 Platforms
- Gamma Delta T Cell Therapy Market Potential By Indications Based On Adoption Rates
In cancer, ?? T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. ?? T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.
The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. ?? T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.
TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic ?? T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global ?? T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other ?? T cell candidates in development for various cancer indications.
One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of ?? T cells and substantiates their role as a new therapeutic strategy.
Globally, most of the research studies on ?? T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply ?? T cell treatments to these more difficult contexts. Geographically, US-based players dominate the ?? T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.
Moving forward, the prospects for ?? T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of ?? T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.
Companies Mentioned
Acepodia
Adicet
Appia Bio
Cytomed Therapeutics
Century Therapeutics
Expression Therapeutics
Immatics
IN8bio
JY BioMed
Legend Biotech
Luminary Therapeutics
PhosphoGam
Takeda
TC Biopharm
ViGenCell
1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies
2. ROLE OF GAMMA DELTA T CELLS IN CANCER
2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy
3. ADVANCED COMBINATION STRATEGIES IN GAMMA DELTA T CELL THERAPY
4. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth
5. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS OVERVIEW
5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status
6. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
7. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia
8. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer
9. GAMMA DELTA T CELLS IN BREAST CANCER
9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer
10. GAMMA DELTA T CELLS IN COLORECTAL CANCER
10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
11. GAMMA DELTA T CELLS IN PANCREATIC CANCER
11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer
12. GAMMA DELTA T CELLS IN LYMPHOMA
12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma
13. GAMMA DELTA T CELL THERAPY IN BRAIN TUMORS
13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors
14. GAMMA DELTA T CELL THERAPY IN HEAD & NECK CANCER
14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer
15. COMPETITIVE LANDSCAPE
15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies
2. ROLE OF GAMMA DELTA T CELLS IN CANCER
2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy
3. ADVANCED COMBINATION STRATEGIES IN GAMMA DELTA T CELL THERAPY
4. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth
5. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS OVERVIEW
5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status
6. GLOBAL GAMMA DELTA T CELL THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
7. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia
8. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer
9. GAMMA DELTA T CELLS IN BREAST CANCER
9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer
10. GAMMA DELTA T CELLS IN COLORECTAL CANCER
10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
11. GAMMA DELTA T CELLS IN PANCREATIC CANCER
11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer
12. GAMMA DELTA T CELLS IN LYMPHOMA
12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma
13. GAMMA DELTA T CELL THERAPY IN BRAIN TUMORS
13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors
14. GAMMA DELTA T CELL THERAPY IN HEAD & NECK CANCER
14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer
15. COMPETITIVE LANDSCAPE
15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell
LIST OF TABLES
Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
LIST OF TABLES
Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 2-5: Functional Advantages Of ?? T Cells for CAR T Cancer Therapy
Figure 2-6: CAR ?? T Cells – Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global – Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global – Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global – Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global – Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global – Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global – Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global – Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global – Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global – Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global – Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-?? T Platform
Figure 4-23: Immatics - ACTallo® Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform – carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-?? T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-?? NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global – Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global – Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global – Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global – Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global – Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study – Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study – Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study – Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study – Initiation & Completion Year
Figure 7-6: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 7-7: Global – Estimated Leukemia Cases, 2025-2031
Figure 7-8: US – Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe – Estimated Leukemia Cases, 2025-2031
Figure 7-10: China – Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan – Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study – Initiation & Completion Year
Figure 8-3: Global – Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US – Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe – Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China – Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan – Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global – Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US – Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe – Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China – Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan – Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study – Initiation & Completion Year
Figure 10-4: Global – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan – Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study – Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study – Initiation & Completion Year
Figure 12-3: Global – Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US – Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe – Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China – Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan – Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study – Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study – Initiation & Completion Year
Figure 13-4: Global – Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US – Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe – Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China – Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan – Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3L: SGN-EGFRd2 Phase 1 (NCT05983133) Study – Initiation & Completion Year
Figure 14-4: Global – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan – Estimated Head & Neck Cancer Cases, 2025-2031
Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan – Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
LIST OF TABLES
Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 2-5: Functional Advantages Of ?? T Cells for CAR T Cancer Therapy
Figure 2-6: CAR ?? T Cells – Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global – Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global – Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global – Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global – Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global – Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global – Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global – Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global – Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global – Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global – Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-?? T Platform
Figure 4-23: Immatics - ACTallo® Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform – carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-?? T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-?? NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global – Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global – Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global – Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global – Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global – Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study – Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study – Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study – Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study – Initiation & Completion Year
Figure 7-6: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 7-7: Global – Estimated Leukemia Cases, 2025-2031
Figure 7-8: US – Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe – Estimated Leukemia Cases, 2025-2031
Figure 7-10: China – Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan – Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study – Initiation & Completion Year
Figure 8-3: Global – Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US – Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe – Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China – Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan – Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global – Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US – Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe – Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China – Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan – Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study – Initiation & Completion Year
Figure 10-4: Global – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China – Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan – Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan – Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study – Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study – Initiation & Completion Year
Figure 12-3: Global – Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US – Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe – Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China – Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan – Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study – Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study – Initiation & Completion Year
Figure 13-4: Global – Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US – Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe – Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China – Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan – Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3L: SGN-EGFRd2 Phase 1 (NCT05983133) Study – Initiation & Completion Year
Figure 14-4: Global – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China – Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan – Estimated Head & Neck Cancer Cases, 2025-2031
